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19th CardioVascular Summit: TCTAP 201419% of the cases had Mid LAD stenosis, 25% had Left Circumﬂex Artery (LCX)
stenosis and 22% had Right Coronary Artery (RCA) proximal stenosis. 74% of the
patients had 3mm diameter stents, 20% had 2.75mm and 6% had 2.5mm. The length
varied from 12 mm to 28 mm. The mean follow up was for 2 years. Four patients
(5.3%) had symptoms suggestive of restenosis out of which one patient (1.3%) died
within 6 weeks duration due to drug default. The remaining 3 patients (4 %) had
symptoms suggestive of restenosis became better with optimization of drugs. None of
them required restudy or repeat revascularization during follow up. Repeat angiogram
couldn’t be done due to ﬁnancial constrains. All other patients were asymptomatic.
Conclusion: The safety proﬁle of BMS is not as inferior as it is thought. Most of the
PCI with BMS were done for Proximal LAD stenosis. The Stent size, proper deploy-
ment, adherence to drugs, modiﬁcation of risk factors reduces the chance of restenosis
in BMS. This study emphasis that BMS is as still a good choice in Rural Health Care
centers in India where there are ﬁnancial constrains and no uniform insurance policy.
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Background: Coronary artery spasm (CAS) is known to be a major cause of
myocardial ischemia. Multi-vessel spasm (MVS) is likely to induce more severe and
prolonged myocardial ischemia than single vessel spasm (SVS). The aim of this study
is to evaluate the impact of MVS vs. SVS as assessed by the intracoronary acetyl-
choline (Ach) provocation test on 3 years clinical outcomes.
Methods: A total of 2,998 consecutive patients (pts) without signiﬁcant coronary
artery disease who underwent an acetylcholine (Ach) provocation test from Nov 2004
to Oct 2010 were enrolled. Among them, a total of 1,609 pts were ﬁnally diagnosed as
Ach positive test and were divided into two groups; MVS group (n¼555pts) and SVS
group (n¼1054 pts). To adjust potential confounders, propensity score matched
(PSM) analysis was performed using the logistic regression model (C-statics: 0.81).
After PSM, total of 1,068 pts (534 pairs) were enrolled for this analysis.
Results: After PSM, the baseline characteristics were balanced between the two
groups. During the ACh test, the response rate to lower ACh doses that induce CAS
was higher in MVS group. However, there were no difference of cumulative clinical
outcomes including mortality, de Novo percutaneous coronary intervention (PCI),
cerebrovascular disease (CVD), and repeated coronary artery angiography (CAG) due
to recurrent chest pain up to 3 years (Table 1). Multivariate analysis showed that MVS
was not a predictor of repeated CAG due to recurrent chest pain (OR:1.4, 95% CI: 0.9-
2.2, p-value¼0.189) and major adverse cardiac and cerebrovascular events (MACCE)
including mortality, PCI, CVD, and repeated CAG due to recurrent chest pain
(OR:1.3, 95% CI: 0.2-6.0, p-value¼0.705).
Conclusion: MVS was associated with higher response rate to lower Ach doses,
showing more vulnerable spastic response. However, MVS was not a predictor of
repeated CAG due to recurrent chest pain and MACE as compared with SVS.TCTAP A-196
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Background: High dose atrovastatin is known to be associated with new onset dia-
betes mellitus (DM) in patients (pts). We investigated the impact of low dose (10mg or
20mg) atorvastatin on the development of new-onset DM based on ﬁve-year clinical
outcomes in Asian patients.S56 JACC Vol 63/12/Suppl S jMethods:We investigated a total of 3,566 consecutive patients (pts) who did not have
DM from January 2004 to September 2009. To adjust potential confounders, a pro-
pensity score matched (PSM) analysis was performed using the logistic regression
model. The primary end-point was the cumulative incidence of new-onset DM which
was deﬁned as having a fasting blood glucose 126 or HbA1c 6.5%. and assessed
to determine the impact of low dose atrovastatin (10mg or 20mg).
Results: Mean follow-up duration was 976278 days in all-pt group, and 993240
days in PSM group. After PSM (C-statistics: 0.851), a total 818 pts were enrolled for
analysis. Adjusted with cox-regression analysis showed that low dose atorvastatin was
an independent predictor of new-onset DM (OR¼1.99, 95%CI 1.00– 3.98, p¼0.050,
ﬁgure A). After PSM analysis, total 98 pts (atorvastatin 10mg, 49 and 20mg, 40) were
analyzed (C-statistics: 0.715). There was no difference in the cumulative incidence of
new-onset DM between the two groups (ﬁgure B).
Conclusion: Low dose atorvastatin therapy was associated with the cumulative
incidence of new-onset DM, however, there was no difference between atrovastatin
10mg and 20mg in Asian population.TCTAP A-197
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Background: Coronary artery calcium scoring (CACS) has been known to be a
predictor of cardiovascular events. However, there is very little information regarding
the relationship among laboratory biomarkers, echocardiographic parameters, and
CACS.
Methods: We investigated clinical characteristics, laboratory biomarkers and echo-
cardiographic parameters of the 1230 patients (pts) underwent echocardiography
and 64-channel multidetector compute tomography (MDCT) from 2007 to
2011. CACS was measured by Agatston score. Biomarker and echocardiographic
parameters were compared between the CACS¼0 group (n¼428) and CACS>0 group
(n¼802).
Results: Diabetes mellitus, hypertension, and hs-CRP>2.0 mg/dl were more frequent
in CACS>0 group. Uric acid, hs-CRP, LVMI, and E/E’ were higher, whereas he-
moglobin, eGFR, calcium, phosphate, LVEF, and HDL-cholesterol were lower in
CACS>0 group as compared with CACS¼0 group. In multivariate analysis adjusted
by gender, age, diabetes, hypertension, smoking history, and GFR, we found that
HDL-cholesterol level was lower in the CACS>0 group, whereas LVMI, and E/E’
were higher in the CACS>0 group (table).
Conclusion: In our study, we found lower HDL-cholesterol, higher LVMI and E/E’
were associated with CACS.April 22–25, 2014 j TCTAP Abstracts/POSTER/Other (Unclassiﬁed)
